TICKERNERD
Menu
EQEQHealthcare · Biotechnology

EQ Stock Forecast: Equillium, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$2.29
+0.88% on the day

The 9 Wall Street analysts covering Equillium, Inc. hold a median 12-month price target of $7 — +205.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$146.5M
Ticker Nerd rank
49 / 100
Median analyst target
$7.00
Analysts covering
9
Total return, dividends reinvested
1W
−3.0%
1M
−12.9%
YTD
+47.7%
1Y
+46.8%
From 52W high
−28.4%
From 52W low
+172.6%
$0.84
$3.20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EQ stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Equillium, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
49 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
93
Growth
83
Size
72
Revisions
63
Volatility
52
Value
34
Quality
26
Issuance
19
Accruals
18

Momentum (93): The shares have been drifting up relative to others.

Accruals (18): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

EQ stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EQ, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26EQHigh $20.00Median $7.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $4.00Median $7.00High $20.00

The green dot is the last close — the median target sits +205.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 July 2026Piper SandlerInitiatesOverweight$20
2 June 2026Roth CapitalReiteratesBuy—
28 May 2026Leerink PartnersUpgradeOutperform—
28 May 2026Roth CapitalReiteratesBuy—
17 Apr 2026Roth CapitalReiteratesBuy—
16 Apr 2026B. Riley SecuritiesInitiatesBuy—
14 Apr 2026Raymond JamesInitiatesStrong Buy—
13 Mar 2026Roth CapitalInitiatesBuy—
28 Mar 2025Leerink PartnersDowngradeMarket Perform—
1 Nov 2024Jones TradingDowngradeHold—
19 Aug 2024HC Wainwright & Co.ReiteratesBuy—
5 June 2024HC Wainwright & Co.ReiteratesBuy—
17 May 2024HC Wainwright & Co.ReiteratesBuy—
2 Apr 2024HC Wainwright & Co.MaintainsBuy—
26 Dec 2023HC Wainwright & Co.MaintainsBuy—
13 Nov 2023HC Wainwright & Co.MaintainsBuy—
14 Aug 2023Cantor FitzgeraldReiteratesOverweight—
14 Aug 2023HC Wainwright & Co.ReiteratesBuy—
14 Aug 2023HC Wainwright& Co.ReiteratesBuy—
15 May 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EQ appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

EQ analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
4
Fundamentals

Equillium, Inc. (EQ) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.9×

Cheaper than 90% of US stocks

Price / sales
—
Price / book
2.6×

Cheaper than 39% of US stocks

EV / EBITDA
−4.7×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−59.0%

Higher than 19% of US stocks

Return on assets
−34.0%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

EQ vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
EQEquillium, Inc.$146.5M
49
TLSATiziana Life Sciences Ltd. (Bermuda)$146.3M
22
LENZLENZ Therapeutics, Inc.$146.4M
24
SPRBSpruce Biosciences, Inc.$148.2M
29
AARDAardvark Therapeutics, Inc.$148.5M
17
CNTBConnect Biopharma Holdings Ltd.$148.6M
22
NRXPNRX Pharmaceuticals, Inc.$149.3M
20

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Equillium, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EQ news & analysis

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

GlobeNewsWire · 13 Aug 2026neutral

Equillium reported Q2 2026 financial results and corporate updates, including the planned initiation of a Phase 1 proof-of-mechanism study of EQ504 in Q4 2026 with data expected approximately six months later. The company reported $57.2 million in cash and cash equivalents expected to fund operations into 2029.

Why it matters — EQ watchers would care because the upcoming EQ504 Phase 1 study timeline provides a key near-term catalyst for the company's lead pipeline candidate.

FAQ

Frequently asked questions about EQ stock

What is the EQ stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Equillium, Inc. have a median 12-month price target of $7, with estimates ranging from $4 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EQ stock a buy right now?

Of the 9 analysts covering Equillium, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Equillium, Inc. 49 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EQ?

As at 22 Aug 2026, Equillium, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (93 of 100).

Will EQ stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +205.7% from the last close, and Ticker Nerd's factor model ranks Equillium, Inc. 49 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EQ stock forecast for 2030?

No analyst covering Equillium, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EQ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $20 over the next 12 months.

How has EQ stock performed over the past year?

Equillium, Inc. returned +46.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Equillium, Inc. do?

Equillium, Inc. is a clinical-stage biotechnology company headquartered in La Jolla, California, focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with significant unmet medical needs.

What is the latest news on EQ?

The most recent item we track (GlobeNewsWire, 13 Aug 2026): "Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights". Equillium reported Q2 2026 financial results and corporate updates, including the planned initiation of a Phase 1 proof-of-mechanism study of EQ504 in Q4 2026 with data expected approximately six months later. The company reported $57.2 million in cash and cash equivalents expected to fund operations into 2029.

Company

About Equillium, Inc.

Equillium, Inc. is a clinical-stage biotechnology company headquartered in La Jolla, California, focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with significant unmet medical needs. The company's lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody currently in phase 3 clinical trials for acute graft-versus-host disease, with additional development in systemic lupus erythematosus and ulcerative colitis. The company also develops EQ101, a selective tri-specific inhibitor targeting multiple interleukin pathways for cutaneous T cell lymphoma treatment, and EQ504, an aryl hydrocarbon receptor modulator being advanced for ulcerative colitis. Equillium serves multiple medical specialties including gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology. The company is advancing its pipeline through strategic financing initiatives and partnerships while maintaining focus on improving capital efficiency and clinical development.

CEO Mr. Bruce Steel · 14 employees · United States · https://www.equilliumbio.com